Kausik Ray

London, United Kingdom

Statin in lipid modification and diabetogenicity A comparison of current guidelines: The good, the bad, and the uncertain Statins Are Enough for the Prevention of CVD

Imperial College London

Kausik Kumar Ray is Professor of Public Health, Department of Primary Care and Public Health, School of Public Health, Imperial College London.

Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.

A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society. Professor Ray has been the national lead investigator, served on the committees or been PI for several major medical trials, including T-EMERGE 8, SOLID TIMI 52, SAVOR TIMI 54, DAL OUTCOMES II, DAL-ACUTE, ODYSSEY, DECLARE TIMI 58, CAMELIA TIMI 61 and THEMIS.

Professor Ray’s research interests have focused on the prevention and reduction of coronary events. He has investigated the early benefits of statin therapy, the advantages of more/less intensive glycaemic control, and the risks/benefits of aspirin therapy. These have influenced AHA/ACC and ESC guidelines. His work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. He continues to investigate the role of lipids, lipoproteins, diabetes, inflammation and thrombosis and coronary events. He has received numerous research grants including from the British Heart Foundation and the Wellcome Trust Project. At St. George’s University of London he heads the Preventative Cardiology Unit and is the Chair of the Integrated Care Pathway for patients with ACS.

Professor Ray has published his research in numerous journals including the NEJM, Lancet, JAMA, Archives of Internal Medicine, Circulation, the Journal of the American College of Cardiology, and the European Heart Journal.

Stay up to date, subscribe to the newsletter

Progression and prevention of atherosclerosis and a translation to relevance.